Impact of XXXX on perioperative mortality after coronary artery bypass graft surgery.

@entity1 @entity4854 @entity413 @entity6
OBJECTIVE: The roles of perioperative @entity4854 and @entity6 in the risk stratification of @entity1 undergoing coronary artery bypass graft surgery are unclear. The aim of this study is to explore the influence of perioperative @entity4854 on postoperative mortality. METHOD: A prospective, observational study of 5050 @entity1 undergoing cardiopulmonary bypass for coronary artery bypass graft surgery at 70 international centers was conducted, with 7500 measured variables per @entity1 and outcomes adjudicated centrally. Postoperative blood @entity413 levels measured from the day of surgery to postoperative day 3 were available for 4799 @entity1 . Multivariable logistic regression was used to determine the association of @entity4854 with hospital mortality. RESULTS: A total of 164 @entity1 died during hospitalization (3.2%). Mortality was significantly higher in the @entity6 population compared with the nondiabetic population (4.2% vs 2.9%; P  =  .02). In nondiabetic @entity1 , maximum postoperative blood @entity413 between 250 and 300 mg/dL (adjusted odds ratio, 2.56; 95% confidence interval, 1.18-5.57; P  =  .02) and maximum blood @entity413 of 300 mg/dL or greater (adjusted odds ratio, 2.74; 95% confidence interval, 1.22-6.16; P  =  .01), compared with maximum blood @entity413 less than 200 mg/dL, and postoperative insulin treatment (adjusted odds ratio, 2.04; 95% confidence interval, 1.12-3.70), were independent risk factors for an increased risk of in-hospital mortality. In @entity6 @entity1 , @entity4854 was not associated with a higher mortality risk. CONCLUSIONS: Postoperative @entity4854 is associated with increased in-hospital mortality in nondiabetic @entity1 after coronary artery bypass graft surgery. In @entity6 @entity1 , @entity4854 was not associated with mortality.
